Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Standard treatments are not available for hilar nonresectable cholangiocarcinoma (NCC). It is unknown whether combination therapy of photodynamic therapy (PDT) plus systemic chemotherapy is superior to PDT alone. Methods: We retrospectively reviewed 68 patients with hilar NCC treated with either PDT plus chemotherapy (PTD-C) or PDT monotherapy (PDT-M). The primary endpoint was the mean overall survival rate. Secondary endpoints included the 1-year survival rate, risk of cholangitic complications, and outcomes, which were evaluated according to the chemotherapy protocol. Results: More than 90% of the study population had advanced hilar NCC Bismuth type III or IV. In the PDT-M group (n=35), the mean survival time was 374 days compared with 520 days in the PDT-C group (n=33, p=0.021). The 1-year survival rate was significantly higher in the PDT-C group compared with the PDT-M group (88% vs 58%, p=0.001) with a significant reduction of mortality (hazard ratio, 0.20; 95% confidence interval, 0.07 to 0.58; p=0.003). Gemcitabine monotherapy resulted in a shorter survival time compared with the gemcitabine combination therapy (mean, 395 days vs 566 days; p=0.09). Cholangitic complications were observed at a similar frequency in the PDT-C and PDT-M groups. Conclusions: Combining repeated PDT with a gemcitabine-based combination therapy might offer a significant survival benefit in patients with hilar NCC.
Abstract
Background/Aims: Standard treatments are not available for hilar nonresectable cholangiocarcinoma (NCC). It is unknown whether combination therapy of photodynamic therapy (PDT) plus systemic chemotherapy is superior to PDT alone. Methods: We retrospectively reviewed 68 patients with hilar NCC treated with either PDT plus chemotherapy (PTD-C) or PDT monotherapy (PDT-M). The primary endpoint was the mean overall survival rate. Secondary endpoints included the 1-year survival rate, risk of cholangitic complications, and outcomes, which were evaluated according to the chemotherapy protocol. Results: More than 90% of the study population had advanced hilar NCC Bismuth type III or IV. In the PDT-M group (n=35), the mean survival time was 374 days compared with 520 days in the PDT-C group (n=33, p=0.021). The 1-year survival rate was significantly higher in the PDT-C group compared with the PDT-M group (88% vs 58%, p=0.001) with a significant reduction of mortality (hazard ratio, 0.20; 95% confidence interval, 0.07 to 0.58; p=0.003). Gemcitabine monotherapy resulted in a shorter survival time compared with the gemcitabine combination therapy (mean, 395 days vs 566 days; p=0.09). Cholangitic complications were observed at a similar frequency in the PDT-C and PDT-M groups. Conclusions: Combining repeated PDT with a gemcitabine-based combination therapy might offer a significant survival benefit in patients with hilar NCC.
참고문헌 (14)
- Khan SA, "Cholangiocarcinoma", Lancet, 366, pp.1303~1314 (2005)
- Nakeeb A, "Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors", Ann Surg, 224, pp.463~473 (1996)
- Ortner ME, "Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study", Gastroenterology, 125, pp.1355~1363 (2003)
- Kiba T, "Single-agent gemcitabine for biliary tract cancers: study outcomes and systematic review of the literature", Oncology, 70, pp.358~365 (2006)
- Scheithauer W, "Review of gemcitabine in biliary tract carcinoma", Semin Oncol, 29(6 Suppl 20), pp.40~45 (2002)
- Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
- Höblinger A, "Feasibility and safety of long-term photodynamic therapy (PDT) in the palliative treatment of patients with hilar cholangiocarcinoma", Eur J Med Res, 16, pp.391~395 (2011)
- Valle JW, "Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials", Ann Oncol, 25, pp.391~398 (2014)
- Park DH, "Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma", Eur J Cancer, 50, pp.1259~1268 (2014)
- Knüppel M, "Combination of conservative and interventional therapy strategies for intra- and extrahepatic cholangiocellular carcinoma: a retrospective survival analysis", Gastroenterol Res Pract, 2012, pp.190708~ (2012)
- Fuks D, "Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice", J Gastroenterol Hepatol, 24, pp.1745~1752 (2009)
- Jayant P. Talreja, "Photodynamic Therapy in Unresectable Cholangiocarcinoma: Not for the Uncommitted", Clinical Endoscopy, 46(4), pp.390~394 (2013), 대한소화기내시경학회
- Gerhardt T, "Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma", Z Gastroenterol, 48, pp.28~32 (2010)
- 홍미진, "Long-Term Outcome of Photodynamic Therapy with Systemic Chemotherapy Compared to Photodynamic Therapy Alone in Patients with Advanced Hilar Cholangiocarcinoma", Gut and Liver, 8(3), pp.318~323 (2014), 거트앤리버 발행위원회